Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104

Grace Therapeutics (GRCE) announced that the U.S. Patent and Trademark Office has issued a U.S. Patent No. 12,414,943, titled “Nimodipine Parenteral Administration”. The new method of use patent, published on September 16, 2025, covers the dosing regimen for I.V. administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104. Grace Therapeutics has established a multi-layered intellectual property estate for GTx-104, including five patents on the composition of the Company’s formulation of nimodipine, which provide patent protection to 2037. The new patent on the I.V. dosing regimen for GTx-104 strengthens the Company’s intellectual property position and extends protection to 2043. Grace has also been granted Orphan Drug Designation from the FDA, which provides GTx-104 seven years of marketing exclusivity in United States upon FDA approval of the Company’s New Drug Application.